Navigation Links
Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
Date:7/10/2008

- Commitment Reflects Eisai's human health care (hhc) Mission to Serve the

Needs of Patients and Families -

WOODCLIFF LAKE, N.J., July 10 /PRNewswire/ -- Eisai Inc., as a member company of the Pharmaceutical Research and Manufacturers of America (PhRMA), today announced that it has renewed its commitment to pursue policies and practices that best serve the needs of patients and the healthcare community in accordance with PhRMA's newly revised Code on Interactions with Healthcare Professionals.

The revised PhRMA Code, effective January 2009, builds upon improvements already made since its adoption and is part of an ongoing industry effort to ensure that pharmaceutical marketing practices comply with the highest ethical standards. The Code was first adopted in 2002 to govern the pharmaceutical industry's relationships with physicians and other healthcare professionals.

Hajime Shimizu, Chairman & CEO, Eisai Corporation of North America and Eisai Inc., and Board Director, PhRMA, stated, "The newly revised PhRMA Code is consistent with Eisai's established Charter of Business Conduct, which is founded on our human health care (hhc) mission to give first thought to patients and their families and to increasing the benefits that health care provides. Eisai strives to uphold the highest ethical and professional standards relevant to interactions with healthcare professionals."

The newly revised Code serves to reaffirm that interactions between company representatives and healthcare professionals remain focused on informing healthcare professionals about products, providing scientific and educational information and supporting medical research and education.

For complete information on PhRMA's Code on Interactions with Healthcare Professionals, please refer to the PhRMA web site at: http://www.phrma.org .

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.

Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit http://www.eisai.com .


'/>"/>
SOURCE Eisai Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
2. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
3. AMERIGROUP Renews Contract with Tennessee
4. WHO Report Says 9.7 Million at Risk of Death from AIDS Today; AHF Renews Call for US Congress to Commit to Scale up Treatment to Seven Million Lives
5. Blue Cross Blue Shield of Arizona Renews EDS Information Technology Services Contract
6. Hall of Fame Shortstop Cal Ripken, Jr. Renews Commitment to Lung Cancer
7. Wiley-Blackwell renews carbon neutral commitment
8. St. Marys Medical Center Renews RCM & Technology With MED3000
9. Governor Rendell Says 2008-09 Budget Renews Commitment to Vulnerable Pennsylvanians
10. FDA Renews its Contract with Beaumont Technology Usability Center for Leadership of Patient Safety Project
11. ABQAURP Renews Agreement with the National Board of Medical Examiners to Oversee Testing Methodology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: